Here's what they said a month ago on the Quarterly call, at least they told us the truth.

"29:30 At this time we will continue the question and answer session...

Christina Deleon: Thank you. 1st question: The HIV combination therapy indication has a fast track designation and 2 out of 3 sections have been submitted to the FDA. Have you received any feedback on those pursuant to a rolling review?

Cyrus: Yes, so we took advantage of leronlimab's indication that we have with the FDA as it relates to the BLA for the HIV MDR population; and the FDA responses through that channel, but I mentioned earlier, we are performing an external audit of the collection and documentation of that clinical data and the results from that audit will inform our next steps BLA."

https://www.reddit.com/r/LeronLimab_Times/com...;context=3